CN102188746B - Artificial extracellular matrix and preparation method thereof - Google Patents
Artificial extracellular matrix and preparation method thereof Download PDFInfo
- Publication number
- CN102188746B CN102188746B CN 201010122277 CN201010122277A CN102188746B CN 102188746 B CN102188746 B CN 102188746B CN 201010122277 CN201010122277 CN 201010122277 CN 201010122277 A CN201010122277 A CN 201010122277A CN 102188746 B CN102188746 B CN 102188746B
- Authority
- CN
- China
- Prior art keywords
- extracellular matrix
- artificial extracellular
- artificial
- chitosan
- lysine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 title claims abstract description 84
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 title claims abstract description 84
- 210000002744 extracellular matrix Anatomy 0.000 title claims abstract description 84
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229920001661 Chitosan Polymers 0.000 claims abstract description 37
- 102000008186 Collagen Human genes 0.000 claims abstract description 25
- 108010035532 Collagen Proteins 0.000 claims abstract description 25
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000004472 Lysine Substances 0.000 claims abstract description 24
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 24
- 239000000243 solution Substances 0.000 claims abstract description 21
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 15
- 239000007864 aqueous solution Substances 0.000 claims abstract description 14
- 239000000017 hydrogel Substances 0.000 claims abstract description 13
- 210000001951 dura mater Anatomy 0.000 claims abstract description 10
- 238000004108 freeze drying Methods 0.000 claims abstract description 9
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 8
- 239000000499 gel Substances 0.000 claims abstract description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 30
- 239000000463 material Substances 0.000 claims description 29
- 239000006193 liquid solution Substances 0.000 claims description 19
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 150000001718 carbodiimides Chemical class 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- -1 diepoxides Chemical compound 0.000 claims description 4
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 3
- AZKVWQKMDGGDSV-BCMRRPTOSA-N Genipin Chemical compound COC(=O)C1=CO[C@@H](O)[C@@H]2C(CO)=CC[C@H]12 AZKVWQKMDGGDSV-BCMRRPTOSA-N 0.000 claims description 3
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 3
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 3
- AZKVWQKMDGGDSV-UHFFFAOYSA-N genipin Natural products COC(=O)C1=COC(O)C2C(CO)=CCC12 AZKVWQKMDGGDSV-UHFFFAOYSA-N 0.000 claims description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 3
- 229920002414 procyanidin Polymers 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 abstract description 8
- 238000006731 degradation reaction Methods 0.000 abstract description 8
- 230000017423 tissue regeneration Effects 0.000 abstract description 8
- 229920001436 collagen Polymers 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 32
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 210000000440 neutrophil Anatomy 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 239000007943 implant Substances 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 239000002158 endotoxin Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000002418 meninge Anatomy 0.000 description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000007541 cellular toxicity Effects 0.000 description 4
- 231100000005 chromosome aberration Toxicity 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000006196 deacetylation Effects 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000820 toxicity test Toxicity 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 235000016936 Dendrocalamus strictus Nutrition 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000000109 fascia lata Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229950000845 politef Drugs 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Landscapes
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses an artificial extracellular matrix and a preparation method thereof. The artificial extracellular matrix is mainly prepared from chitosan, collagen, sodium hyaluronate and lysine, wherein the mass ratio of the chitosan to the collagen to the sodium hyaluronate to the lysine is (0.1-400):(1-400):(0.1-5000):(0.1-5000). The preparation method of the artificial extracellular matrix comprises the following steps: mixing a chitosan colloidal solution, a collagen hydrogel, a sodium hyaluronate aqueous solution and a lysine aqueous solution, and adding a crosslinking agent to react; and carrying out freeze-drying on the crosslinked mixed gel, thus obtaining the artificial extracellular matrix. The artificial extracellular matrix disclosed by the invention has good controllable degradation property, biocompatibility and tissue repair performance, and can be used as a clinically applicable artificial dura mater.
Description
Technical field
The present invention relates to artificial extracellular matrix and preparation method thereof.
Background technology
The neurosurgical doctor often utilizes from the body cranial periosteum in operation clinically, cervical muscle fascia, medicated cap shape chamber film, autologous tissue's cerebral dura mater repairing such as fascia lata are damaged, but not only spended time is long to get these materials, sometimes these are organized self to sustain damage and can not be utilized, the position that has self does not just have complete available tissue, often causes not having enough areas to be utilized.Transplanting its hetero-organization not only needs the art preplanning, prepares second operative site, increases operation and anesthesia duration, also will produce new wound.In addition, even use autologous tissue, the anoxia regular meeting of autologous tissue induces the inflammatory reaction of below cortex, causes the adhesion between meninges and the brain.
The artificial dura mater material of clinical practice at present mainly is divided into allogeneic material, foreign material, synthetic material and four types of natural material.
The allogeneic meninges is to be used for clinical non-repair materials from body the earliest.This material is to obtain from the human body brain of death, processes the back as commodity selling through lyophilization.Advantage is: preparation is simple, can directly use, implant conveniently, can long preservation, and the physiological property that has kept fresh meninges is early stage fibroblastic infiltration and revascularization, eliminates rejection in the normal structure around it can be fused to.But the allosome cerebral dura mater has 3 significant weakness: the one, and material source is restricted, and the donor lacks, but also has the problem of ethics aspect; The 2nd, the existence of infectious protein prime factor (Prion), investigation report according to Japanese health ministry in March, 1997 issue, 766 Creutz Fil spy-Jacob (Creutzfeldt-JakobSyndrome (disease), CJD) among the patient, 28 examples live through the dry duramater reparation art of human body, compare with the millionth spontaneous generation rate of JCD, made the people JCD sickness rate of cerebral dura mater kposthesis apparently higher than the natural occurrence rate, for this reason, the ban of the dry meninges of allosome is used in the Health and human services department issue, World Health Organization (WHO) also issues and bans use of the dural urgent notice of people's allosome in the operation simultaneously, so some country has cancelled the freezing human cerebral dura mater of use as patching material at present; The 3rd, the expensive ability to bear that surpasses the patient.
Both at home and abroad, xenogenesis cerebral dura mater repair materials is in the more kind of clinical practice, mainly is with bovine pericardium and the preparation of Cor Caprae seu ovis peplos.The advantage of xenogenesis dural repairment material is to be convenient to obtain, and preparation is simple, and leakageresistance is better.But because the safety problem of animal derived material in recent years, the country that has has limited the use of such material.
The easy processing and forming of synthetic material is easy to sterilization, does not have the risk of the virus transmitted.The material that is usually used in the repairing of hard brain (ridge) film has silicone rubber, polypropylene, politef etc.But these materials only have the function of filling-up mechanically, and do not have the ability of short tissue regeneration, especially under the bad situation of material processed, and day long seepage that is easy to generate, even can cause capillary hemorrhage, produce chronic inflammatory disease.
Natural material is the natural biological macromolecular substances of purifying through processing, and the material that can be used for the pachymeninx repairing has collagen, chitosan, chondroitin sulfate etc.They are called as the artificial extracellular matrix, are the favorable tissue engineering scaffold materials.They also can be used as the good substrate of cell growth except having the mechanical barrier effect, the function of transfer sell chemical signal is arranged, and therefore can promote tissue regeneration.In this process, material itself is degraded, and finally the autologous tissue of being healed substitutes.This point modern regenerative medicine just requires and advocates.But these materials also have shortcoming, and are too fast such as degradation rate, so that self new meninges also is not completed into and material is degraded.
Summary of the invention
The purpose of this invention is to provide a kind of artificial extracellular matrix that good controllable degradation property is arranged and preparation method thereof.
Artificial extracellular matrix provided by the present invention mainly is prepared from by chitosan, collagen protein, hyaluronate sodium and lysine.
Artificial extracellular matrix of the present invention, wherein, described chitosan, described collagen protein, described hyaluronate sodium and described lysine are crosslinked by cross-linking agent.
Artificial extracellular matrix of the present invention, wherein, the mass ratio of described chitosan, described collagen protein, described hyaluronate sodium and described lysine is (0.1～400): (1～400): (0.1～5000): (0.1～5000).
Artificial extracellular matrix of the present invention, wherein, described cross-linking agent be selected from following any or appoint several: formaldehyde, glutaraldehyde, carbodiimides, diepoxides, genipin and procyanidin.
Artificial extracellular matrix's provided by the present invention preparation method comprises the steps:
Chitosan gum liquid solution, collagen protein hydrogel, aqueous solution of sodium hyaluronate and lysine solution are mixed, add the cross-linking agent reaction again;
Crosslinked good mixed gel lyophilization obtains described artificial extracellular matrix.
Artificial extracellular matrix's of the present invention preparation method, wherein, the mass ratio of described chitosan, described collagen protein, described hyaluronate sodium and described lysine is (0.1～400): (1～400): (0.1～5000): (0.1～5000).
Artificial extracellular matrix's of the present invention preparation method, wherein, described cross-linking agent be selected from following any or appoint several: formaldehyde, glutaraldehyde, carbodiimides, diepoxides, genipin and procyanidin.
Artificial extracellular matrix's of the present invention preparation method, wherein, described chitosan gum liquid solution is the acetic acid solution of 0.1～5mg/ml chitosan, the concentration of acetic acid is 0.1ml/100ml～0.5ml/100ml in the described acetic acid solution; The concentration of collagen protein is 1～50mg/ml in the described collagen protein hydrogel; The concentration of hyaluronate sodium is 0.1～100mg/ml in the described aqueous solution of sodium hyaluronate; The concentration of lysine is 0.1～100mg/ml in the described lysine solution.
Artificial extracellular matrix's of the present invention preparation method, wherein, described cryodesiccated temperature is-80 ℃～40 ℃.
Artificial extracellular matrix of the present invention has good controllable degradation property, and excellent biological compatibility energy and tissue repair performance can be used as clinical suitable novel artificial cerebral dura mater.
The specific embodiment
Embodiment 1, artificial extracellular matrix
0.01ml/100ml acetic acid solution in add the purified chitosan of deacetylation 60%, stirred 2 hours, be mixed with the chitosan gum liquid solution of 0.1mg/ml.
With 0.1mg/ml chitosan gum liquid solution, 1mg/ml collagen protein hydrogel, 0.1mg/ml putting into crosslinked jar, aqueous solution of sodium hyaluronate and 0.1mg/ml lysine solution mix, 0.1mg/ml chitosan gum liquid solution, 1mg/ml collagen protein hydrogel, 0.1mg/ml the volume ratio of aqueous solution of sodium hyaluronate and 0.1mg/ml lysine solution is 1: 1: 1: 1, adding carbodiimides again is mixed, the mass ratio of carbodiimides and chitosan is 0.001: 1,50 ℃ were reacted 2 hours, be cooled to room temperature, the lyophilizing dish vacuum lyophilization under-80 ℃～40 ℃ conditions of packing into of crosslinked good mixed gel was obtained the artificial extracellular matrix in 48 hours.
Artificial extracellular matrix's outward appearance is the lamellar rectangle of white, and there is crystal gloss on the surface, and visible material is random short fiber network shape structure under naked eyes or the magnifier, knows that with feel certain toughness is arranged, the clean inviolateness of appearance.
Artificial extracellular matrix's length is 4.32～4.56cm, and wide is 4.24～4.54cm, and thick is 0.5～0.9cm.
Artificial extracellular matrix's chemical property: artificial extracellular matrix's residue on ignition 0.3%, pH value 7.1, artificial extracellular matrix's content of beary metal (in lead) is less than 10ug/g.
Artificial extracellular matrix's biology performance: steriling test (GB/T 19973.2-2005) artificial extracellular matrix meets sterility specifications.The cytotoxicity that cell toxicity test (GB/T 16886.5-2003) detects the artificial extracellular matrix is 0～1 grade.Bacterial endotoxin test (EN455-3-2000) detects artificial extracellular matrix's bacterial endotoxin less than 0.5EU/ml.Salmonella reversion test (GB/T 16886.3-2008) detects negative.Chromosomal aberration test (GB/T 16886.3-2008) detects negative.Micronucleus test (GB/T 16886.3-2008) detects negative.Sensitization test (STT) (GB/T 16886.10-2005) detects no sensitivity response.Acute for the no acute living body toxic reaction of poison test (ISO 10993-11:2006) detection.Implant back local response test (ISO 10993-6:2007), after the artificial extracellular matrix implanted for 1 week, more lymphocyte, neutrophil cell and a small amount of multinucleated giant cell are arranged around sample material, have granulation tissue to hold around the material.After implanting for 4 weeks, more lymphocyte, neutrophil cell are arranged around sample material.After implanting for 12 weeks, implant site has few lymphocyte, neutrophil cell, and sample material is degraded and absorbed, and no naked eyes can be distinguished foreign body.
Artificial extracellular matrix in the The above results explanation present embodiment has good controllable degradation property, excellent biological compatibility energy and tissue repair performance.
Embodiment 2, artificial extracellular matrix
0.5ml/100ml acetic acid solution in add the purified chitosan of deacetylation 70%, stirred 10 hours, be mixed with the chitosan gum liquid solution of 5mg/ml.
With 5mg/ml chitosan gum liquid solution, 50mg/ml collagen protein hydrogel, 100mg/ml aqueous solution of sodium hyaluronate and 100mg/ml lysine solution are put into crosslinked jar and are mixed, 5mg/ml chitosan gum liquid solution, 50mg/ml collagen protein hydrogel, the volume ratio of 100mg/ml aqueous solution of sodium hyaluronate and 100mg/ml lysine solution is 80: 80: 50: 50, add glutaraldehyde again, the volume ratio of glutaraldehyde and chitosan gum liquid solution is to be mixed at 1: 400,50 ℃ were reacted 2 hours, be cooled to room temperature, the lyophilizing dish vacuum lyophilization under-60 ℃～30 ℃ conditions of packing into of crosslinked good mixed gel was obtained the artificial extracellular matrix in 48 hours.
Artificial extracellular matrix's outward appearance is the lamellar rectangle of white, and there is crystal gloss on the surface, and visible material is random short fiber network shape structure under naked eyes or the magnifier, knows that with feel certain toughness is arranged, the clean inviolateness of appearance.
Artificial extracellular matrix's length is 4.32～4.56cm, and wide is 4.24～4.54cm, and thick is 0.5～0.9cm.
Artificial extracellular matrix's chemical property: artificial extracellular matrix's residue on ignition 0.5%, pH value 7.1, artificial extracellular matrix's content of beary metal (in lead) is less than 10ug/g.
Artificial extracellular matrix's biology performance: steriling test (GB/T 19973.2-2005) artificial extracellular matrix meets sterility specifications.The cytotoxicity that cell toxicity test (GB/T 16886.5-2003) detects the artificial extracellular matrix is 0～1 grade.Bacterial endotoxin test (EN455-3-2000) detects artificial extracellular matrix's bacterial endotoxin less than 0.5EU/ml.Salmonella reversion test (GB/T 16886.3-2008) detects negative.Chromosomal aberration test (GB/T 16886.3-2008) detects negative.Micronucleus test (GB/T 16886.3-2008) detects negative.Sensitization test (STT) (GB/T 16886.10-2005) detects no sensitivity response.Acute for the no acute living body toxic reaction of poison test (ISO 10993-11:2006) detection.Implant back local response test (ISO 10993-6:2007), after the artificial extracellular matrix implanted for 1 week, more lymphocyte, neutrophil cell and a small amount of multinucleated giant cell are arranged around sample material, have granulation tissue to hold around the material.After implanting for 4 weeks, more lymphocyte, neutrophil cell are arranged around sample material.After implanting for 12 weeks, implant site has few lymphocyte, neutrophil cell, and sample material is degraded and absorbed, and no naked eyes can be distinguished foreign body.
Artificial extracellular matrix in the The above results explanation present embodiment has good controllable degradation property, excellent biological compatibility energy and tissue repair performance.
Embodiment 3, artificial extracellular matrix
0.3ml/100ml acetic acid solution in add the purified chitosan of deacetylation 85%, stirred 30 hours, be mixed with the chitosan gum liquid solution of 2mg/ml.
With 2mg/ml chitosan gum liquid solution, 10mg/ml collagen protein hydrogel, 10mg/ml aqueous solution of sodium hyaluronate and 20mg/ml lysine solution are put into crosslinked jar and are mixed, 2mg/ml chitosan gum liquid solution, 10mg/ml collagen protein hydrogel, the volume ratio of 10mg/ml aqueous solution of sodium hyaluronate and 20mg/ml lysine solution is 80: 20: 30: 30, adding diepoxides again is mixed, the volume ratio of diepoxides and chitosan gum liquid solution is 1: 500,50 ℃ were reacted 2 hours, be cooled to room temperature, the lyophilizing dish vacuum lyophilization under-40 ℃～40 ℃ conditions of packing into of crosslinked good mixed gel was obtained the artificial extracellular matrix in 48 hours.
Artificial extracellular matrix's outward appearance is the lamellar rectangle of white, and there is crystal gloss on the surface, and visible material is random short fiber network shape structure under naked eyes or the magnifier, knows that with feel certain toughness is arranged, the clean inviolateness of appearance.
Artificial extracellular matrix's length is 4.32～4.56cm, and wide is 4.24～4.54cm, and thick is 0.5～0.9cm.
Artificial extracellular matrix's chemical property: artificial extracellular matrix's residue on ignition 0.4%, pH value 7.2, artificial extracellular matrix's content of beary metal (in lead) is less than 10ug/g.
Artificial extracellular matrix's biology performance: steriling test (GB/T 19973.2-2005) artificial extracellular matrix meets sterility specifications.The cytotoxicity that cell toxicity test (GB/T 16886.5-2003) detects the artificial extracellular matrix is 0～1 grade.Bacterial endotoxin test (EN455-3-2000) detects artificial extracellular matrix's bacterial endotoxin less than 0.5EU/ml.Salmonella reversion test (GB/T 16886.3-2008) detects negative.Chromosomal aberration test (GB/T 16886.3-2008) detects negative.Micronucleus test (GB/T 16886.3-2008) detects negative.Sensitization test (STT) (GB/T 16886.10-2005) detects no sensitivity response.Acute for the no acute living body toxic reaction of poison test (ISO 10993-11:2006) detection.Implant back local response test (ISO 10993-6:2007), after the artificial extracellular matrix implanted for 1 week, more lymphocyte, neutrophil cell and a small amount of multinucleated giant cell are arranged around sample material, have granulation tissue to hold around the material.After implanting for 4 weeks, more lymphocyte, neutrophil cell are arranged around sample material.After implanting for 12 weeks, implant site has few lymphocyte, neutrophil cell, and sample material is degraded and absorbed, and no naked eyes can be distinguished foreign body.
Artificial extracellular matrix in the The above results explanation present embodiment has good controllable degradation property, excellent biological compatibility energy and tissue repair performance.
Embodiment 4, artificial extracellular matrix
0.1ml/100ml acetic acid solution in add the purified chitosan of deacetylation 99%, stirred 60 hours, be mixed with the chitosan gum liquid solution of 3mg/ml.
With 3mg/ml chitosan gum liquid solution, 30mg/ml collagen protein hydrogel, 30mg/ml aqueous solution of sodium hyaluronate and 30mg/ml lysine solution are put into crosslinked jar and are mixed, 3mg/ml chitosan gum liquid solution, 30mg/ml collagen protein hydrogel, the volume ratio of 30mg/ml aqueous solution of sodium hyaluronate and 30mg/ml lysine solution is 50: 30: 10: 10, adding formaldehyde again is mixed, the volume ratio of formaldehyde and chitosan gum liquid solution is 1: 600,50 ℃ were reacted 2 hours, be cooled to room temperature, the lyophilizing dish vacuum lyophilization under-80 ℃～30 ℃ conditions of packing into of crosslinked good mixed gel was obtained the artificial extracellular matrix in 48 hours.
Artificial extracellular matrix's outward appearance is the lamellar rectangle of white, and there is crystal gloss on the surface, and visible material is random short fiber network shape structure under naked eyes or the magnifier, knows that with feel certain toughness is arranged, the clean inviolateness of appearance.
Artificial extracellular matrix's length is 4.32～4.56cm, and wide is 4.24～4.54cm, and thick is 0.5～0.9cm.
Artificial extracellular matrix's chemical property: artificial extracellular matrix's residue on ignition 0.4%, pH value 7.1, artificial extracellular matrix's content of beary metal (in lead) is less than 10ug/g.
Artificial extracellular matrix's biology performance: steriling test (GB/T 19973.2-2005) artificial extracellular matrix meets sterility specifications.The cytotoxicity that cell toxicity test (GB/T 16886.5-2003) detects the artificial extracellular matrix is 0～1 grade.Bacterial endotoxin test (EN455-3-2000) detects artificial extracellular matrix's bacterial endotoxin less than 0.5EU/ml.Salmonella reversion test (GB/T 16886.3-2008) detects negative.Chromosomal aberration test (GB/T 16886.3-2008) detects negative.Micronucleus test (GB/T 16886.3-2008) detects negative.Sensitization test (STT) (GB/T 16886.10-2005) detects no sensitivity response.Acute for the no acute living body toxic reaction of poison test (ISO 10993-11:2006) detection.Implant back local response test (ISO 10993-6:2007), after the artificial extracellular matrix implanted for 1 week, more lymphocyte, neutrophil cell and a small amount of multinucleated giant cell are arranged around sample material, have granulation tissue to hold around the material.After implanting for 4 weeks, more lymphocyte, neutrophil cell are arranged around sample material.After implanting for 12 weeks, implant site has few lymphocyte, neutrophil cell, and sample material is degraded and absorbed, and no naked eyes can be distinguished foreign body.
Artificial extracellular matrix in the The above results explanation present embodiment has good controllable degradation property, excellent biological compatibility energy and tissue repair performance.
Above embodiment is described preferred implementation of the present invention; be not that scope of the present invention is limited; design under the prerequisite of spirit not breaking away from the present invention; various distortion and improvement that the common engineers and technicians in this area make technical scheme of the present invention all should fall in the definite protection domain of claims of the present invention.
Claims (3)
1. an artificial extracellular matrix mainly is prepared from by chitosan, collagen protein, hyaluronate sodium and lysine; Described chitosan, described collagen protein, described hyaluronate sodium and described lysine are crosslinked by cross-linking agent; The mass ratio of described chitosan, described collagen protein, described hyaluronate sodium and described lysine is (0.1～400): (1～400): (0.1～5000): (0.1～5000);
Described artificial extracellular matrix's preparation method comprises the steps: chitosan gum liquid solution, collagen protein hydrogel, aqueous solution of sodium hyaluronate and lysine solution are mixed, and adds the cross-linking agent reaction again; Crosslinked good mixed gel lyophilization obtains described artificial extracellular matrix;
Described cryodesiccated temperature is-80 ℃～40 ℃, and described chitosan gum liquid solution is the acetic acid solution of 0.1～5mg/ml chitosan, and the concentration of acetic acid is 0.1ml/100ml～0.5ml/100ml in the described acetic acid solution; The concentration of collagen protein is 1～50mg/ml in the described collagen protein hydrogel; The concentration of hyaluronate sodium is 0.1～100mg/ml in the described aqueous solution of sodium hyaluronate; The concentration of lysine is 0.1～100mg/ml in the described lysine solution;
Wherein, described refrigerating process is: with the lyophilizing dish vacuum lyophilization 48 hours under-80 ℃～40 ℃ conditions of packing into of crosslinked good mixed gel;
Described artificial extracellular matrix's length is 4.32～4.56cm, and wide is 4.24～4.54cm, and thick is 0.5～0.9cm; Described artificial extracellular matrix's chemical property is one of following:
1) artificial extracellular matrix's residue on ignition is 0.3%, 0.4% or 0.5%, pH value 7.1, artificial extracellular matrix's content of beary metal in lead less than 10ug/g;
2) artificial extracellular matrix's residue on ignition is 0.4%, pH value 7.2, artificial extracellular matrix's content of beary metal in lead less than 10ug/g.
2. artificial extracellular matrix according to claim 1 is characterized in that: described cross-linking agent be selected from following any or appoint several: formaldehyde, glutaraldehyde, carbodiimides, diepoxides, genipin and procyanidin.
3. claim 1 or the 2 described artificial extracellular matrix application in preparation artificial dura mater material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010122277 CN102188746B (en) | 2010-03-11 | 2010-03-11 | Artificial extracellular matrix and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010122277 CN102188746B (en) | 2010-03-11 | 2010-03-11 | Artificial extracellular matrix and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102188746A CN102188746A (en) | 2011-09-21 |
| CN102188746B true CN102188746B (en) | 2013-08-14 |
Family
ID=44598173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010122277 Expired - Fee Related CN102188746B (en) | 2010-03-11 | 2010-03-11 | Artificial extracellular matrix and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102188746B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12447235B2 (en) | 2019-02-21 | 2025-10-21 | Uniwersytet Jagiellonski | Hydrogel hybrid material, method of its preparation and application |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130244943A1 (en) | 2011-09-06 | 2013-09-19 | Allergan, Inc. | Hyaluronic acid-collagen matrices for dermal filling and volumizing applications |
| CN103435837B (en) * | 2013-09-06 | 2014-11-05 | 杨树林 | A kind of preparation method of recombinant human collagen biological sponge |
| CN105903081A (en) * | 2015-12-14 | 2016-08-31 | 上海其胜生物制剂有限公司 | Preparation method of novel double layer proteoglycan-based restoration material |
| US20230040919A1 (en) * | 2019-12-26 | 2023-02-09 | Allergan, Inc. | Crosslinked ha-collagen hydrogels as dermal fillers |
| CN115516077B (en) * | 2020-06-22 | 2024-12-06 | 凸版印刷株式会社 | Gel composition and method for producing the same, and three-dimensional tissue and method for producing the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228096C (en) * | 2002-05-14 | 2005-11-23 | 暨南大学 | Biologically induced artificial active cornea and its preparing process |
| CN1235646C (en) * | 2003-11-03 | 2006-01-11 | 刘永庆 | Method for preparing multifunctional biological repair material |
| US20060200245A1 (en) * | 2005-03-07 | 2006-09-07 | Sdgi Holdings, Inc. | Materials, devices, and methods for in-situ formation of composite intervertebral implants |
| US20090035350A1 (en) * | 2007-08-03 | 2009-02-05 | John Stankus | Polymers for implantable devices exhibiting shape-memory effects |
-
2010
- 2010-03-11 CN CN 201010122277 patent/CN102188746B/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12447235B2 (en) | 2019-02-21 | 2025-10-21 | Uniwersytet Jagiellonski | Hydrogel hybrid material, method of its preparation and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102188746A (en) | 2011-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102188746B (en) | Artificial extracellular matrix and preparation method thereof | |
| Wang et al. | Multilayer scaffold of electrospun PLA–PCL–collagen nanofibers as a dural substitute | |
| US11850324B2 (en) | Three-dimensional (3-D) printing inks made from natural extracellular matrix molecules | |
| Laquerriere et al. | Experimental evaluation of bilayered human collagen as a dural substitute | |
| ES2672622T3 (en) | Preparation of regenerative tissue frames | |
| Zhang et al. | Development of a visible light, cross-linked GelMA hydrogel containing decellularized human amniotic particles as a soft tissue replacement for oral mucosa repair | |
| ES2665284T3 (en) | Membrane | |
| US9585984B2 (en) | Antibacterial cornea repair material and preparation method thereof | |
| CA2964501C (en) | A biomaterial scaffold for regenerating the oral mucosa | |
| Beena et al. | Optically clear silk fibroin films with tunable properties for potential corneal tissue engineering applications: a process–property–function relationship study | |
| Chen et al. | Novel chitosan hydrogel formed by ethylene glycol chitosan, 1, 6-diisocyanatohexan and polyethylene glycol-400 for tissue engineering scaffold: in vitro and in vivo evaluation | |
| JP7209377B2 (en) | Tissue-engineered medical devices | |
| Terasaka et al. | Fibrin glue and polyglycolic acid nonwoven fabric as a biocompatible dural substitute | |
| CN101020082A (en) | Bone repairing material and its prepn process and use | |
| CN105233336B (en) | Sericin nerve trachea and the preparation method and application thereof | |
| US20080254088A1 (en) | Shaped bodies based on a cross-linked, gelatinous material, method for producing such bodies and use of the bodies | |
| CN104189009B (en) | Vascularization promoting small intestine submucosa temperature-sensitive material and preparation method thereof | |
| US20080003205A1 (en) | Tympanic Membrane Repair Constructs | |
| Li et al. | Bone substitute biomedical material of multi-(amino acid) copolymer: in vitro degradation and biocompatibility | |
| Sun et al. | In vivo study of alginate hydrogel conglutinating cells to polycaprolactone vascular scaffolds fabricated by electrospinning | |
| Maher et al. | Evaluation of a novel propylene oxide—treated collagen material as a dural substitute | |
| Gould et al. | Harnessing the regenerative potential of purified bovine dental pulp and dentin extracellular matrices in a chitosan/alginate hydrogel | |
| Zhang et al. | Silk fibroin composite membranes for application in corneal regeneration | |
| EP3664857B1 (en) | A process for producing a two-stage crosslinked biopolymer membrane and a biopolymer membrane made in this process | |
| CN117482289A (en) | Preparation method of a dual-network multifunctional hydrogel with antibacterial and drug sequential release capabilities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130814 Termination date: 20140311 |